The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced funding for the construction of two National Biocontainment Laboratories (NBLs) and nine Regional Biocontainment Laboratories (RBLs). "These awards to build high-level biosafety facilities are a major step towards being able to provide Americans with effective therapies, vaccines and diagnostics for diseases caused by agents of bioterror as well as for naturally occurring emerging infections such as SARS and West Nile virus," says Health and Human Services Secretary Tommy G. Thompson.

One-time grants of approximately $120 million each will fund construction of the NBLs, while the RBLs will receive one-time grants of between $7 and $21 million each in construction funds. Each institution is also required to provide matching funds.

NBLs

Institution: Boston University
Construction Location: Boston University Medical Center
Principal Investigator: Mark Klempner, M.D.

Institution: University of Texas Medical Branch at Galveston
Construction Location: University of Texas Medical Branch at Galveston
Principal Investigator: Stanley Lemon, M.D

RBLs

Institution (Location): Colorado State University (Fort Collins)
Construction Location: Foothills Campus, Fort Collins, CO
Principal Investigator: Anthony Frank, D.V.M., Ph.D.

Institution (Location): Duke University (Durham)
Construction Location: Duke University Medical Center
Principal Investigator: R.S. Williams, M.D.

Institution: Tulane University (New Orleans)
Construction Location: Tulane National Primate Research Center, Covington, LA
Principal Investigator: Paul Whelton, M.D., B.Ch., B.A.O.

Institution: University of Alabama at Birmingham
Construction Location: University of Alabama at Birmingham School of Medicine
Principal Investigator: Rich
'"/>

Contact: NIAID Press Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Sep-2003

Page: 1 2 3
Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice